DCAF15 and lymphoma: Interestingly, RBM39 degradation was described as a biomarker of indisulam response in acute myeloid leukemia and DCAF15 levels were shown to correlate with indisulam response in hematopoietic and lymphoid cancers (Han et al, 2017; Hsiehchen et al, 2020).